Navi Mumbai (Maharashtra) [India], April 24: Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, announces their results for the quarter ended March 31, 2025. For Q4FY25, the company reported revenue from operations of INR 187.2 crore, reflecting a 21% year-over-year (YoY) growth. Normalized EBITDA for the quarter stood at INR 65.3 crore, marking a robust 78% YoY increase. Profit after tax (PAT), excluding exceptional items, reached INR 32.5 crore, which represents an impressive 88% YoY growth.
Key highlights for Q4FY25:
- Consolidated revenue increased by 21% year-over-year (YoY) with Pathology and Radiology segments growing by 23% YoY and 7% YoY respectively
- Total volume in FY25 grew to 167.9 million, largest by far on volume
- Revenue from franchise surged by 22% YoY, and partnership revenue saw 24% YoY growth
- Consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%
- Standalone normalized EBITDA grew by 72% YoY, while PAT* increased by 72% YoY
- Consolidated normalized EBITDA grew by 78% YoY, while PAT* increased by 88% YoY
- Recommended a final dividend of INR 21 per equity share subject to the approval of shareholders at the ensuing shareholders meeting
- Consolidated cash reserves as of March 2025 is INR 191.8 Cr
- Opened new labs in Bhagalpur and Kashmir
Consolidated income statement for Q4FY25 and FY25:
| Quarter | Annual | |||||
| INR Crore | Q4FY25 | Q4FY24 | YoY | FY25 | FY24 | YoY |
| Revenue from operations | 187.2 | 154.2 | 21% | 687.3 | 571.9 | 20% |
| Gross margin | 137.7 | 107.6 | 28% | 496.2 | 405.2 | 22% |
| Normalized EBITDA (before ESOP) | 65.3 | 36.7 | 78% | 209.9 | 153.1 | 37% |
| Reported EBITDA | 57.4 | 33.8 | 70% | 189.2 | 137.8 | 37% |
| Profit after tax incl. exceptional item | 21.3 | 17.2 | 24% | 90.0 | 69.8 | 29% |
| Profit after tax excl. exceptional item | 32.5 | 17.2 | 88% | 101.2 | 69.8 | 45% |
| Key metrics | ||||||
| Gross margin% | 74% | 70% | 72% | 71% | ||
| Normalized EBITDA% | 35% | 24% | 31% | 27% | ||
| Reported EBITDA% | 31% | 22% | 28% | 24% | ||
| PAT incl. exceptional item% | 11% | 11% | 13% | 12% | ||
| PAT excl. exceptional item% | 17% | 11% | 14% | 12% | ||
* PAT excluding exceptional item of INR 11.2 Cr pertaining to reversal of deferred tax asset created in previous years against the impairment of investment in NHL.
If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.
